From: Yoga management of breast cancer-related lymphoedema: a randomised controlled pilot-trial
QOL | Group mean ± SD b-8 | Between group changes 0-8 |  | Group mean ± SD 8b-12 | Between group changes 8b-12 | ||||
---|---|---|---|---|---|---|---|---|---|
Variable Gp(n) | Week 0 M ± SD | Week M ± SD | ∆int-∆con 0–8 MD; (95% CI) | P(0–8) | Variable Gp(n) | Week 8b M ± SD | Week 12 M ± SD | ∆int-∆con 8b-12 MD; (95% CI) | p(8b-12) |
Total QOL | |||||||||
Con(11) | 7.91 ± 1.22 | 7.45 ± 1.44 | 1.04; (-0.19 to 2.26) | 0.437†| Con(10) | 7.40 ± 1.51 | 7.40 ± 1.51 | 0.44; (-0.38 to 1.27) | 0.290 |
Int(12) | 6.83 ± 2.55 | 7.42 ± 1.24 | Int(9) | 7.33 ± 0.87 | 7.78 ± 1.09 | ||||
Function | |||||||||
Con(11) | 1.36 ± 0.40 | 1.30 ± 0.36 | -0.13; (-0.34 to 0.09) | 0.364†| Cont(10) | 1.31 ± 0.38 | 1.35 ± 0.33 | 0.13; (-0.07 to 0.33) | 0.210 |
Int(12) | 1.48 ± 0.48 | 1.30 ± 0.31 | Int(9) | 1.34 ± 0.33 | 1.51 ± 0.14 | ||||
Appearance | |||||||||
Con(11) | 1.56 ± 0.81 | 1.56 ± 0.86 | -0.07; (-0.34 to 0.20) | 0.627 | Con(10) | 1.60 ± 0.69 | 1.60 ± 0.69 | 0.10; (-.25 to 0.45) | 0.578 |
Int(11) | 1.50 ± 0.34 | 1.43 ± 0.33 | Int(9) | 1.42 ± 0.37 | 1.52 ± 0.37 | ||||
Symptoms | |||||||||
Con(11) | 1.69 ± 0.37 | 1.82 ± 0.54 | -0.44; (-0.74 tro -0.13) | 0.038†| Con(10) | 1.90 ± 0.49 | 1.73 ± 0.47 | 0.17; (-0.05 to 0.39) | 0.124 |
Int(12) | 2.11 ± 0.61 | 1.81 ± 0.40 | Int(9) | 1.91 ± 0.38 | 1.91 ± 0.40 | ||||
Emotions | |||||||||
Con(11) | 1.71 ± 0.56 | 1.61 ± 0.49 | -0.18; (-0.62 to 0.26) | 0.430 | Con(10) | 1.62 ± 0.52 | 1.60 ± 0.56 | 0.04; (-0.24 to 0.31) | 0.801 |
Int(12) | 1.86 ± 0.74 | 1.58 ± 0.7 | Int(9) | 1.44 ± 0.45 | 1.46 ± 0.43 |